No Prescription |
 |
 | ||
|
EMESET Zofran |
|
| ||
No Prescription » Prescription Drugs 7 » EMESET Zofran Ondansetron is used for: Preventing nausea and vomiting due to cancer chemotherapy or surgery. Ondansetron blocks the actions of chemicals in the body that can trigger nausea and vomiting. Buy EMESET Zofran and other Prescription Drugs 7 products online at Medstore. Buy Online at Medstore - Click Here!
About EMESET Zofran: Product Type: Prescription Drugs 7 EMESET - ( Zofran Zofran ODT Generic Ondansetron ) EMESET - (Zofran Zofran ODT Generic Ondansetron) Zofran Zofran ODT Generic Ondansetron 4mg tabs 20 (2x10) 8mg tabs 20 (2 x 10) Zofran Zofran ODT Generic Ondansetron EMESET -
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
